Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,073 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, Hu G, Luo Z, Fu Z, Qu S, Feng W, Chen X, Lin S, Zhang W, Li X, Sun Y, Lin Z, Lin Q, Lei F, Long J, Hong J, Huang X, Zeng L, Wang P, He X, Zhang B, Yang Q, Zhang X, Zou J, Fang W, Zhang L. Yang Y, et al. Among authors: luo z. Lancet Oncol. 2021 Aug;22(8):1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23. Lancet Oncol. 2021. PMID: 34174189 Clinical Trial.
Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y, Chen D, Liang J, Gao J, Luo Z, Wang R, Liu W, Huang C, Ning X, Liu M, Huang H. Lu Y, et al. Among authors: luo z. BMC Cancer. 2019 Dec 30;19(1):1262. doi: 10.1186/s12885-019-6459-6. BMC Cancer. 2019. PMID: 31888551 Free PMC article. Clinical Trial.
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
Qu W, Fu C, Han W, Luo H, Quan J, Chen L, Liao Y, Hu C, Hu H, Niu Y, Xu D, Chen M, Chen J, Liu Y, Chen G, Luo Z, Shi B, Sun Y, Zhou F, Zhou A. Qu W, et al. Among authors: luo h, luo z. Eur J Cancer. 2024 Jul;205:114096. doi: 10.1016/j.ejca.2024.114096. Epub 2024 May 10. Eur J Cancer. 2024. PMID: 38772302 Clinical Trial.
Magnetic Domain Wall Energy Landscape Engineering in a Ferrimagnet.
Ma Y, Fang X, Yan F, Wang L, Yao R, Meng M, Qin P, Yang J, Liu Z, Luo Z, Ning S, Luo F. Ma Y, et al. Among authors: luo z. Nano Lett. 2024 Dec 26. doi: 10.1021/acs.nanolett.4c04916. Online ahead of print. Nano Lett. 2024. PMID: 39722580
12,073 results
You have reached the last available page of results. Please see the User Guide for more information.